沙粒病毒的抗病毒药物-猫眼课题宝

沙粒病毒的抗病毒药物

批准号：

8076702

负责人：

SEAN M AMBERG

金额：

$177.92万

依托单位：

SIGA TECHNOLOGIES, INC.

依托单位国家：

美国

项目类别：

财政年份：

2011

资助国家：

美国

项目状态：

已结题

起止时间：

2011-08-17 至 2016-07-31

来源：

https://reporter.nih.gov/project-details/8076702

关键词：

Animal Model Animals Antiviral Agents Arenavirus Binding Biological Biological Availability Categories Cavia Chemicals Chemistry Clinical Data Development Dose Drug Interactions Drug Kinetics Drug resistance Evaluation Foundations Genetic Genetic Determinism Glycoproteins Goals Human In Vitro Investigational New Drug Application Junin virus Lassa Fever Lassa virus Lead Libraries Macaca fascicularis Metabolism Modeling Monitor Mutation Organ Pharmaceutical Chemistry Pharmaceutical Preparations Pharmacology Pharmacology and Toxicology Predisposition Preparation Proteins Reporting Resistance Ribavirin Safety Screening procedure Series Solubility Specificity Structure Structure-Activity Relationship Tacaribe Complex Viruses Testing Toxic effect Toxicology Variant Viral Viral Hemorrhagic Fevers Virus analog analytical method animal efficacy base chemical synthesis cost effective drug metabolism drug resistant virus efficacy evaluation fitness genotoxicity hemorrhagic fever virus in vivo inhibitor/antagonist large scale production nonhuman primate pharmacophore pre-clinical prevent programs protective efficacy small molecule

项目摘要

项目成果

SEAN M AMBERG的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

DESCRIPTION (provided by applicant): The goal of the program described here is to develop an antiviral drug for treating and preventing Lassa fever and other hemorrhagic fevers of arenavirus origin. Previous library screening identified several good candidate small molecule inhibitors of Lassa virus entry. Subsequent in vitro and in vivo characterization identified a potent series, ST-193, with broad- spectrum activity against 5 distinct Category A hemorrhagic fever Arenaviruses. This series has shown protective efficacy in two animal models of Lassa fever, guinea pigs and cynomolgus monkeys. The specific objective of this application is to optimize this chemical series to identify an appropriate candidate for preclinical development and to collect the necessary data to support the submission of an application for an Investigational New Drug (IND).

期刊论文(0)

专著(0)

科研奖励(0)

会议论文